Advanced

Evaluating the role of leukotriene-modifying drugs in asthma management : Are their benefits ‘losing in translation’?

Pyasi, Kanchan; Tufvesson, Ellen LU and Moitra, Subhabrata (2016) In Pulmonary Pharmacology and Therapeutics 41. p.52-59
Abstract

Leukotrienes (LTs) initiate a cascade of reactions that cause bronchoconstriction and inflammation in asthma. LT-modifying drugs have been proved very effective to reduce inflammation and associated exacerbation however despite some illustrious clinical trials the usage of these drugs remains overlooked because the evidence to support their utility in asthma management has been mixed and varied between studies. Although, there are plenty of evidences which suggest that the leukotriene-modifying drugs provide consistent improvement even after just the first oral dose and reduce asthma exacerbations, the beneficial effect of these drugs has remained sparse and widely debated. And these beneficial effects are often overlooked because most... (More)

Leukotrienes (LTs) initiate a cascade of reactions that cause bronchoconstriction and inflammation in asthma. LT-modifying drugs have been proved very effective to reduce inflammation and associated exacerbation however despite some illustrious clinical trials the usage of these drugs remains overlooked because the evidence to support their utility in asthma management has been mixed and varied between studies. Although, there are plenty of evidences which suggest that the leukotriene-modifying drugs provide consistent improvement even after just the first oral dose and reduce asthma exacerbations, the beneficial effect of these drugs has remained sparse and widely debated. And these beneficial effects are often overlooked because most of the clinical studies include a mixed population of asthmatics who do not respond to LT-modifiers equally. Therefore, in the present era of personalized medicine, it is important to properly stratify the patients and non-invasive measurements of biomarkers may warrant the possibility to characterize biological/pathological pathway to direct treatment to those who will benefit from it. Endotyping based on individual's leukotriene levels should probably ascertain a subgroup of patients that would clearly benefit from the treatment even though the trial fails to show overall significance. In this article, we have methodically evaluated contemporary literature describing the efficacy of LT-modifying drugs in the management of asthma and highlighted the importance of phenotyping the asthmatics for better treatment outcomes.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Asthma, Bronchoconstriction, Eicosanoids, Leukotriene, Montelukast
in
Pulmonary Pharmacology and Therapeutics
volume
41
pages
8 pages
publisher
Elsevier
external identifiers
  • Scopus:84988624801
ISSN
1094-5539
DOI
10.1016/j.pupt.2016.09.006
language
English
LU publication?
yes
id
e67a9246-61ac-41d4-9101-343b5962ece0
date added to LUP
2016-10-12 13:07:27
date last changed
2016-10-13 03:00:02
@misc{e67a9246-61ac-41d4-9101-343b5962ece0,
  abstract     = {<p>Leukotrienes (LTs) initiate a cascade of reactions that cause bronchoconstriction and inflammation in asthma. LT-modifying drugs have been proved very effective to reduce inflammation and associated exacerbation however despite some illustrious clinical trials the usage of these drugs remains overlooked because the evidence to support their utility in asthma management has been mixed and varied between studies. Although, there are plenty of evidences which suggest that the leukotriene-modifying drugs provide consistent improvement even after just the first oral dose and reduce asthma exacerbations, the beneficial effect of these drugs has remained sparse and widely debated. And these beneficial effects are often overlooked because most of the clinical studies include a mixed population of asthmatics who do not respond to LT-modifiers equally. Therefore, in the present era of personalized medicine, it is important to properly stratify the patients and non-invasive measurements of biomarkers may warrant the possibility to characterize biological/pathological pathway to direct treatment to those who will benefit from it. Endotyping based on individual's leukotriene levels should probably ascertain a subgroup of patients that would clearly benefit from the treatment even though the trial fails to show overall significance. In this article, we have methodically evaluated contemporary literature describing the efficacy of LT-modifying drugs in the management of asthma and highlighted the importance of phenotyping the asthmatics for better treatment outcomes.</p>},
  author       = {Pyasi, Kanchan and Tufvesson, Ellen and Moitra, Subhabrata},
  issn         = {1094-5539},
  keyword      = {Asthma,Bronchoconstriction,Eicosanoids,Leukotriene,Montelukast},
  language     = {eng},
  month        = {12},
  pages        = {52--59},
  publisher    = {ARRAY(0x6f0d250)},
  series       = {Pulmonary Pharmacology and Therapeutics},
  title        = {Evaluating the role of leukotriene-modifying drugs in asthma management : Are their benefits ‘losing in translation’?},
  url          = {http://dx.doi.org/10.1016/j.pupt.2016.09.006},
  volume       = {41},
  year         = {2016},
}